Search
Search Results
-
Screening and treatment of latent tuberculosis in patients with solid tumors and systemic cancer therapy
IntroductionTuberculosis is one of the infectious diseases with greater morbidity and mortality worldwide. Cancer causes an important...
-
Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study
BackgroundTuberculosis has a major global impact. Immunocompetent hosts usually control this disease, resulting in an asymptomatic latent...
-
Tuberculosis reactivation demonstrated by choroiditis and inflammatory choroidal neovascular membrane in a patient treated with immune checkpoint inhibitors for malignant mucosal melanoma
PurposeTo describe a complex case of ocular tuberculosis reactivation with anterior uveitis, choroiditis and inflammatory choroidal neovascular...
-
Latent tuberculosis in children and youth with type 1 diabetes mellitus in Dar es Salaam, Tanzania: a cross section survey
BackgroundData for latent tuberculosis in patients with type 1 Diabetes in Africa is limited. We assessed the prevalence of latent tuberculosis in...
-
From immunology to artificial intelligence: revolutionizing latent tuberculosis infection diagnosis with machine learning
Latent tuberculosis infection (LTBI) has become a major source of active tuberculosis (ATB). Although the tuberculin skin test and interferon-gamma...
-
Safety and outcome of treatment of latent tuberculosis infection in liver transplant recipients
PurposeLiver transplant (LT) recipients have an increased risk of tuberculosis (TB), which is associated with higher mortality rates. This...
-
Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infection
ObjectiveTo evaluate the safety of secukinumab (SEC) in the treatment of patients with axial spondyloarthritis (axSpA) and concurrent hepatitis B...
-
Exploring the link between cardiovascular risk factors and manifestations in latent tuberculosis infection: a comprehensive literature review
BackgroundThe global burden of tuberculosis (TB) and cardiovascular disease (CVD) is overt, and the prevalence of this double burden disease remains...
-
COVID-19 and chronic diabetes: the perfect storm for reactivation tuberculosis?: a case series
BackgroundThe coronavirus disease 2019 pandemic is predicted to have a net negative effect on tuberculosis control, with an estimated excess of...
-
Randomized Controlled Trial of Clinical Guidelines Versus Interactive Decision-Support for Improving Medical Trainees’ Confidence with Latent Tuberculosis Care
BackgroundIn order to eliminate tuberculosis (TB) in the USA, primary care providers must take on an expanded role in the diagnosis and management of...
-
Screening Practices for Latent Tuberculosis Infection in Clinical Trials Evaluating Treatments for Chronic Hepatitis B Virus Infection
Latent tuberculosis infection (LTBI) prevalence among adults with chronic hepatitis B (CHB) is two times higher than LTBI prevalence in the general...
-
Diabetes mellitus and latent tuberculosis infection: an updated meta-analysis and systematic review
BackgroundPrevious studies have demonstrated an association between diabetes mellitus (DM) and latent tuberculosis infection (LTBI). This study was...
-
Facilitators and barriers to latent tuberculosis infection treatment among primary healthcare workers in Malaysia: a qualitative study
BackgroundHealthcare workers (HCWs) have an increased risk of active and latent tuberculosis infection (LTBI) compared to the general population....
-
Protective Effect of BCG and Neutrophil-to-Lymphocyte Ratio on Latent Tuberculosis in End Stage Renal Disease
IntroductionBacillus Calmette-Guérin (BCG) vaccination has been reported to be protective against latent tuberculosis infection (LTBI) in the general...
-
Dual latent tuberculosis screening with tuberculin skin tests and QuantiFERON-TB assays before TNF-α inhibitor initiation in children in Spain
Tumor-necrosis-factor-α inhibitors (anti-TNF-α) are associated with an increased risk of tuberculosis (TB) disease, primarily due to reactivation of...
-
Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review
BackgroundWe conducted a systematic review examining the cost effectiveness of a 3-month course of isoniazid and rifapentine, known as 3HP, given by...
-
Gut microbiota composition can reflect immune responses of latent tuberculosis infection in patients with poorly controlled diabetes
BackgroundDiabetes mellitus (DM) is a major risk factor for tuberculosis (TB). Evidence has linked the DM-related dysbiosis of gut microbiota to...
-
National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic disease modifying antirheumatic drugs (DMARDs)
This publication provides a thorough analysis of the most relevant topics concerning the management of latent tuberculosis when using biologic and...
-
Tuberculosis reactivation at ileum following immune checkpoint inhibition with pembrolizumab for metastatic nasopharyngeal carcinoma: a case report
BackgroundTuberculosis (TB) reactivation has been increasingly identified following immune checkpoint inhibitor (ICI) therapy for cancer patients....
